About Guanine nucleotide-binding protein subunit alpha-14
Guanine nucleotide-binding protein subunit alpha-14 (GNA14) is a protein
from Homo sapiens identified by UniProt accession
O95837, 355 residues long.
MolForge cross-references it against 0 known binders and
82 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein subunit alpha-14 |
|---|
| UniProt accession | O95837 |
|---|
| Gene | GNA14 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 355 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (82)
Diseases linked to this target (Open Targets).
- tufted angioma · score 0.41
- Choreoacanthocytosis · score 0.33
- chorea-acanthocytosis · score 0.33
- venous thromboembolism · score 0.31
- kaposiform hemangioendothelioma · score 0.26
- pyogenic granuloma · score 0.26
- breast adenocarcinoma · score 0.25
- neurodegenerative disease · score 0.23
- cutaneous melanoma · score 0.16
- pathological myopia · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95837-F1 | alphafold | PREDICTED | 93.51 | — |
Amino-acid sequence (355 residues)
MAGCCCLSAE EKESQRISAE IERQLRRDKK DARRELKLLL LGTGESGKST FIKQMRIIHG SGYSDEDRKG FTKLVYQNIF TAMQAMIRAM DTLRIQYVCE QNKENAQIIR EVEVDKVSML SREQVEAIKQ LWQDPGIQEC YDRRREYQLS DSAKYYLTDI DRIATPSFVP TQQDVLRVRV PTTGIIEYPF DLENIIFRMV DVGGQRSERR KWIHCFESVT SIIFLVALSE YDQVLAECDN ENRMEESKAL FKTIITYPWF LNSSVILFLN KKDLLEEKIM YSHLISYFPE YTGPKQDVRA ARDFILKLYQ DQNPDKEKVI YSHFTCATDT DNIRFVFAAV KDTILQLNLR EFNLV
Explore Guanine nucleotide-binding protein subunit alpha-14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets